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Abstract
AIM: To investigate whether the patatin-like phosph-
olipase domain containing-3  gene (PNPLA3 ) I148M 
polymorphism is associated with steatosis, fibrosis stage, 
and cirrhosis in hereditary hemochromatosis (HH). 
METHODS: We studied 174 consecutive unrelated 
homozygous for the C282Y HFE mutation of HH 
(C282Y+/+ HH) patients from Northern Italy, for whom 
the presence of cirrhosis could be determined based on 
histological or clinical criteria, without excessive alcohol 
intake (< 30/20 g/d in males or females) or hepatitis B 
virus and hepatitis C virus viral hepatitis. Steatosis was 
evaluated in 123 patients by histology (n  = 100) or ul-
trasound (n  = 23). The PNPLA3 rs738409 single nucle-
otide polymorphism, encoding for the p.148M protein 
variant, was genotyped by a Taqman assay (assay on 
demand, Applied Biosystems). The association of the 
PNPLA3 I148M protein variant (p.I148M) with steatosis, 
fibrosis stage, and cirrhosis was evaluated by logistic 
regression analysis.
RESULTS: PNPLA3 genotype was not associated with 
metabolic parameters, including body mass index (BMI), 
the presence of diabetes, and lipid levels, but the pres-
ence of the p.148M variant at risk was independently 
associated with steatosis [odds ratio (OR) 1.84 per 
p.148M allele, 95% confidence interval (CI): 1.05-3.31; 
P  = 0.037], independently of BMI and alanine amino-
transaminase (ALT) levels. The p.148M variant was 
also associated with higher aspartate aminotransferase 
(P  = 0.0014) and ALT levels (P  = 0.017) at diagnosis, 
independently of BMI and the severity of iron overload. 
In patients with liver biopsy, the 148M variant was 
independently associated with the severity (stage) of 
fibrosis (estimated coefficient 0.56 ± 0.27, P  = 0.041). 
In the overall series of patients, the p.148M variant was 
associated with cirrhosis in lean (P  = 0.049), but not 
in overweight patients (P  = not significant). At logistic 
regression analysis, cirrhosis was associated with BMI 
≥ 25 (OR 1.82, 95% CI: 1.02-3.55), ferritin > 1000 
ng/mL at diagnosis (OR 19.3, 95% CI: 5.3-125), and 
with the G allele in patients with BMI < 25 (OR 3.26, 
95% CI: 1.3-10.3). 
CONCLUSION: The PNPLA3 I148M polymorphism may 
represent a permissive factor for fibrosis progression in 
patients with C282Y+/+ HH. 
BRIEF ARTICLE
Online Submissions: http://www.wjgnet.com/1007-9327office
wjg@wjgnet.com
doi:10.3748/wjg.v18.i22.2813
2813 June 14, 2012|Volume 18|Issue 22|WJG|www.wjgnet.com
World J Gastroenterol  2012 June 14; 18(22): 2813-2820
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2012 Baishideng. All rights reserved.
© 2012 Baishideng. All rights reserved.
Key words: Fatty liver; Fibrosis; Hemochromatosis; HFE 
protein; Iron overload; Patatin-like phospholipase domain 
containing-3  gene; Steatosis
Peer reviewers: Kostas Pantopoulos, Professor, Lady Davis In-
stitute for Medical Research, McGill University, 3755 Cote-Ste-
Catherine Road, Montreal H3T 1E2, Canada; Yuichi Yoshida, As-
sistant Professor, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan
Valenti L, Maggioni P, Piperno A, Rametta R, Pelucchi S, Mari-
ani R, Dongiovanni P, Fracanzani AL, Fargion S. Patatin-like 
phospholipase domain containing-3 gene I148M polymorphism, 
steatosis, and liver damage in hereditary hemochromatosis. World 
J Gastroenterol 2012; 18(22): 2813-2820  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v18/i22/2813.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v18.i22.2813
INTRODUCTION
Hereditary hemochromatosis (HH) is a genetic disorder 
of  iron metabolism characterized by defective release 
or activity of  hepcidin, the hepatic hormone that in-
hibits iron absorption by binding and inactivating fer-
roportin[1]. HH is most frequently related to hampered 
hepcidin up-regulation by iron stores as a consequence 
of  homozygosity for the C282Y mutation in the HFE 
gene[2]. The resultant increase in serum iron leads to pro-
gressive accumulation in the liver and other parenchymal 
organs, however, although hepatic iron overload leads to 
progressive liver fibrosis and cirrhosis in some affected 
individuals, the phenotypic expression is unpredictable 
and highly variable[3].
Indeed, liver disease is the most frequent clinical mani-
festation of  homozygous for the C282Y HFE mutation 
of  HH (C282Y+/+ HH), but it is now clear that only a 
proportion of  subjects carrying this genotype will ever 
develop hepatic fibrosis[4]. Most of  C282Y +/+ male 
subjects develop expanded iron stores during life, whereas 
due to the physiological iron losses during fertile age, 
the female gender represents a major protective factor. 
In population based screening studies it has been shown 
that between 75% and 94% of  C282Y+/+ males develop 
elevated transferrin saturation, and that 64% to 68% will 
have an increased serum ferritin[4-8]. However, even in 
males, the prediction of  risk of  clinical disease remains 
uncertain[9].
The recognition of  the incomplete penetrance of  
HH has led to a search for genetic and other modifiers 
of  clinical expression. HH expression may be influenced 
at different levels[9]: (1) by factors affecting iron load-
ing, including sex and genetic factors (genes regulating 
hepcidin expression, beta-thalassemia trait[10]); (2) by fac-
tors influencing the progression to liver disease, such as 
hepatic steatosis[11], viral hepatitis, genes regulating pro-
inflammatory cytokines and oxidative injury[12,13]; and 
(3) by those regulating both, such as alcohol intake and 
hepatitis C virus (HCV) infection[14,15]. 
There is established evidence that increased body 
mass (BMI) and the metabolic syndrome[16] are strong risk 
factors for hepatic steatosis[17] and that steatosis acceler-
ates the progression of  liver diseases by favoring oxida-
tive stress and hepatocellular damage. In 214 C282Y +/+ 
patients[11], a significant association between steatosis and 
the presence of  fibrosis was detected. This relationship 
remained significant after adjustment for confounding 
factors such as alcohol intake and iron loading. 
Recently, the rs738409 C > G single nucleotide poly-
morphism (SNP) of  patatin-like phospholipase domain contain-
ing-3 gene (PNPLA3), encoding for the I148M protein 
variant (p.I148M), has been identified as a determinant 
of  liver fat content and of  the susceptibility to develop 
steatohepatitis and progressive fibrosis[18-23]. Importantly, 
PNPLA3 genotype influences liver fat independently of  
body mass, dyslipidemia, and insulin resistance[24,25]. 
Since hepatic steatosis has been reported to influence 
HH expression, the aim of  this study was to determine 
whether the PNPLA3 I148M variant predisposes to the 
development of  steatosis, and to progressive liver dam-
age, as evaluated fibrosis stage and the presence of  cir-
rhosis, in patients with pure C282Y+/+ HH stratified 
according to the presence of  overweight.
MATERIALS AND METHODS
Patients
From 232 consecutive unrelated C282Y+/+ HH patients 
referred to two centers in the Milan area of  Northern 
Italy, we excluded subjects with alcohol intake > 30/20 g 
per day in male/female, hepatitis B virus (HBV) and/or 
HCV infections, and other cofactors of  liver disease (n = 
30), and those with an uncertain diagnosis of  cirrhosis or 
incomplete clinical data (n = 28), and finally included 174 
patients in the analysis (Figure 1). DNA samples were 
available for all patients. 
Diagnosis of  cirrhosis was based upon liver histology 
(n = 100) or clinical evidence (n = 74): in particular, cir-
rhosis was diagnosed by liver histology in 26 patients, and 
by clinical criteria in 6 cases (in the presence of  hepatic 
decompensation or of  portal hypertension; liver biopsy 
was not indicated for ethical reasons), whereas it was 
excluded by liver histology in 74 cases, and by clinical cri-
teria in the remaining 68 cases (when liver biopsy was not 
indicated and not performed for ethical reasons). 
Tissue sections were stained with hematoxylin and eo-
sin, impregnated with silver for reticulin framework, and 
stained with trichrome for collagen and Perls for iron. 
Steatosis was considered present when involving at least 
5% of  hepatocytes and graded according to Kleiner[26]. 
Tissue iron was graded according to Scheuer[27]. Fibrosis 
was scored according to Ishak[28]. The minimum biopsy 
size was 1.7 cm and the number of  portal areas was 10. 
For data analysis, a fibrosis stage of  6 was attributed to 
patients with a clinical diagnosis of  cirrhosis.
Ultrasonographic diagnosis of  steatosis at diagnosis 
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by an experienced operator (available in 123) was based 
on evident ultrasonographic contrast between the hepatic 
and right renal parenchyma of  the right intercostal sono-
gram in the midaxillary line, or abnormally intense, high-
level echoes arising from the hepatic parenchyma, and 
was graded on a three-grade scale as none, mild, or severe 
in accordance with intensity[29]. 
Cirrhosis was considered clinically absent only if  all 
these conditions were satisfied: (1) age < 40 years; (2) 
alanine aminotransaminase (ALT) within normal levels; 
and (3) ferritin < 1000 ng/mL. These criteria have been 
shown to rule out not only cirrhosis, but also advanced 
fibrosis with high specificity in patients with C282Y+/+ 
HH without viral hepatitis and excessive alcohol intake[30].
Overweight was considered present when BMI > 25 
kg/m2. For each patient we collected data on sex, age, 
geographical origins, BMI, alcohol consumption, aspartate 
aminotransferase (AST), ALT and γ-glutamyl transferase 
(GGT) levels, ferritin, transferrin saturation percentage, 
total cholesterol, high density lipoprotein cholesterol and 
triglycerides levels, glucose, and type 2 diabetes[31]. Clini-
cal features of  the patients included are shown in Table 1. 
Informed written consent was obtained from each patient 
included. The study conformed to the ethical guidelines of  
the 1975 Declaration of  Helsinki and was approved by the 
Institutional Review Board of  the Institutions involved.
Genetic analysis
DNA was extracted from peripheral blood by the phe-
nol-chloroform method. Success rate in extracting DNA 
was 100% for each study group. The PNPLA3 rs738409 
SNP was genotyped by a Taqman assay (assay on de-
mand for rs738409, Applied Biosystems, Foster City, CA, 
United States) by personnel unaware of  patients and con-
trols clinical status. Post-polymerase chain reaction allelic 
discrimination was carried out measuring allele-specific 
fluorescence on the Opticon2 detection system (MJ Re-
search, Waltham, MA, United States). Random samples 
were confirmed by direct genotyping which provided 
concordant results in all cases[19]. Quality controls were 
performed to verify the reproducibility of  the results. 
Valid genotypic data were obtained for 100% of  subjects 
analyzed. 
Statistical analysis
Values are expressed as mean ± SD or median (inter-
quartile range) according to distribution. Mean values 
were compared by analysis of  variance or Wilcoxon, and 
frequencies by F test and χ 2 test for trend, when appro-
priate. The study had a > 85% power to detect a two-fold 
higher risk of  cirrhosis in carriers of  the 148M allele, but 
only 33% to detect a 33% increased risk. Independent 
predictors of  AST and ALT levels were analyzed by gen-
eralized linear model. The association of  the PNPLA3 
p.148M variant with fibrosis was evaluated by ordinal 
logistic regression analysis, and with the presence of  ste-
atosis and cirrhosis was evaluated by multivariate logistic 
regression analysis. P values were considered significant 
when < 0.05 (two-tailed). Analyses were carried out with 
JMP 6.0 statistical analysis software (SAS Institute Inc., 
Cary, NC, United States).
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232 consecutive unrelated C282Y+/+ HH patients 
from Northern Italy with available DNA samples
202 patients with 
“pure” C282Y+/+ HH
30 patients excluded because of 
chronic viral hepatitis, or alcohol 
intake > 20/30 g/d in M/F
174 patients 
(100 with biopsy) 
with C282Y+/+ HH
28 patients in whom the presence 
of cirrhosis could not be excluded 
or BMI not available
Figure 1  Study flow chart. C282Y+/+ HH: Homozygous for the C282Y 
HFE mutation of hereditary hemochromatosis; M/F: Male/female; BMI: Body 
mass index.
1Available in 123 patients. I: Ileucine; M: Methionine; n: Number; F: 
Female; DAI: Daily alcohol intake; BMI: Body mass index; HDL: High 
density lipoprotein cholesterol; TS: Transferrin saturation; AST: Aspartate 
aminotransferase; ALT: Alanine aminotransaminase; GGT: γ-glutamyl 
transferase.
Table 1  Demographic, anthropometric, clinical, and histolog-
ical features, as evaluated at diagnosis, of 174 Italian patients 
with homozygous for the C282Y HFE mutation of heredi-
tary hemochromatosis subdivided according to the PNPLA3 
I148M genotype
All patients PNPLA3 I148M genotype P  value
I/I I/M M/M
n (%) 174 82 (47) 70 (40) 22 (13)
Age (yr)   47 ± 13   46 ± 13   47 ± 14   50 ± 11 0.22
Gender F (%) 49 (28) 24 (30) 19 (27)  6 (27) 0.79
DAI (g)    10 (0-20)    10 (0-20)      5 (0-20)    10 (0-20) 0.98
BMI (kg/m2) 24 ± 3 24 ± 3 24 ± 3 25 ± 2 0.11
Diabetes (%) 16 (9) 7 (9) 6 (9)   3 (14) 0.57
Total 
cholesterol 
(mg/dL)
191 ± 44 197 ± 37 186 ± 50 182 ± 44 0.25
HDL 
cholesterol 
(mg/dL)
53 ± 16 53 ± 14 53 ± 17 57 ± 15 0.47
Triglycerides 
(mg/dL)
120 ± 66 123 ± 64 122 ± 74 99 ± 35 0.30
TS % 80 ± 16 80 ± 16 79 ± 15 81 ± 23 0.94
Ferritin 1000 1018 947 1053 0.36
(ng/mL) (509-1800) (490-1813) (516-1732) (504-2101)
AST (IU/mL) 34 ± 21 31 ± 16 35 ± 24 44 ± 29   0.019
ALT (IU/mL) 46 ± 32 41 ± 26 47 ± 34 55 ± 45 0.06
GGT (IU/mL)      24 (16-37)      24 (17-37)      24 (15-38)      23 (14-30) 0.95
Steatosis1 (%) 55 (48) 18 (31) 29 (58)   8 (53)   0.014
Advanced 
fibrosis %
18 (10)   9 (11)   7 (10) 2 (9) 0.95
(Ishak 4) %
Cirrhosis 32 (18) 13 (16) 14 (20)   5 (23) 0.39
(Ishak 5-6) %
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ciated with demographic or anthropometric features, daily 
alcohol intake, metabolic parameters, including the pres-
ence of  diabetes, and the severity of  iron overload (Table 1). 
However, we observed an association between PNPLA3 
and transaminases, which was significant for AST levels [P 
for trend (i.e., for increasing levels with increasing number 
of  148M alleles) = 0.019 for AST and P for trend = 0.06 
for ALT], whereas GGT levels were not affected. Indepen-
dent predictors of  AST and ALT levels in the generalized 
linear model are shown in Table 3; variables included were 
selected by a stepwise mixed regression model. Both AST 
and ALT levels were significantly and independently cor-
related with younger age, higher iron parameters (TS% and 
ferritin levels), GGT levels, BMI, and the number (0-2) of  
148M PNPLA3 alleles (P = 0.0014 and P = 0.017 for AST 
and ALT levels, respectively).
Association of PNPLA3 gene genotype with severity of 
fibrosis and cirrhosis
We next evaluated whether PNPLA3 genotype influences 
fibrosis stage.  At ordinal regression analysis conducted in 
patients with liver biopsy or clinical diagnosis of  cirrhosis 
(n = 106; shown in Table 4), fibrosis stage (0-6) was in-
dependently associated with gender, ALT and GGT val-
ues, and PNPLA3 p.148M alleles (estimated coefficient 
of  correlation 0.56 ± 0.27, P = 0.04). Possibly due to 
the relatively low number of  patients studied, PNPLA3 
genotype was not significantly associated with cirrhosis 
in the whole cohort (Table 1), although the presence of  
the 148M allele was nominally significantly associated 
with cirrhosis in patients with BMI < 25 (P = 0.05, P = 
0.1 after Bonferroni correction; Figure 3). Importantly, 
positivity for the PNPLA3 148M variant was associated 
with an increase in the prevalence of  steatosis in subjects 
with BMI < 25, which reached levels similar to those 
of  overweight patients (BMI < 25: 17/37, 46% vs 7/32, 
22%, P = 0.036; BMI ≥ 25: 22/31, 71% vs 10/26, 38%; 
P = 0.017 for patients positive and negative for the 148M 
variant, respectively). Independent predictors of  cirrhosis 
are shown in Table 2. At logistic regression analysis, cir-
rhosis was associated with BMI ≥ 25 (OR 1.82, 95% CI: 
RESULTS
Association of PNPLA3 gene genotype with steatosis
We first sought to confirm the association of  the G al-
lele encoding for the p.148M variant with liver fat in 
C282Y+/+ HH. The frequency distribution of  the 
rs738409 PNPLA3 SNP (P = not significant for Hardy-
Weinberg equilibrium testing) in patients subdivided ac-
cording to the presence of  steatosis is shown in Figure 
2 (P = 0.014). The frequency of  the G allele was 0.41 in 
patients with and 0.26 in those without steatosis (P = 0.011), 
and did not change after the exclusion of  patients with 
ultrasonographic evaluation of  the presence of  steatosis. 
Independent predictors of  steatosis at logistic regression 
analysis, considered as independent variables selected by 
a stepwise mixed regression model, are shown in Table 
2. Steatosis was independently associated with BMI (P = 
0.008) and PNPLA3 genotype [odds ratio (OR) 1.84 per G 
allele, 95% confidence interval (CI): 1.05-3.31; P = 0.037].
Association of PNPLA3 gene genotype with liver 
enzymes
As expected, PNPLA3 genotype was not significantly asso-
CC
CG
GG
No steatosis (n  = 68) Steatosis (n  = 55)
10%
31%
59%
15%
52%
33%
Figure 2  Frequency distribution of the rs738409 C > G single nucleotide polymorphism, encoding for the I148M protein variant, in 123 patients with homo-
zygous for the C282Y HFE mutation of hereditary hemochromatosis subdivided according to the presence of steatosis (P = 0.015). 
Table 2  Independent predictors of steatosis and cirrhosis 
in Italian patients with homozygous for the C282Y HFE 
mutation of hereditary hemochromatosis, as evaluated by 
logistic regression analysis
OR 95% CI P  value
Independent predictors of steatosis n = 123
BMI (per kg/m2) 1.22 1.06-1.42  0.008
ALT (per IU/mL) 1.01 0.99-1.02  0.353
PNPLA3 genotype (per p allele) 1.84 1.05-3.31  0.037
Independent predictors of cirrhosis n = 174
Ferritin (ng/mL)   1.001 1.000-1.002 < 0.0001
Diabetes 0.54 0.26-1.16  0.101
BMI (>/m2) 1.83 1.02-3.57  0.055
PNPLA3 p allele present (BMI > 25) 0.76 0.37-1.53  0.453
PNPLA3 p allele present (BMI ≤ 25) 3.26 1.28-10.30  0.024
OR: Odds ratio; CI: Confidence interval; BMI: Body mass index; ALT: 
Alanine aminotransaminase; p.148M: PNPLA3 rs738409 148Met protein 
variant. 
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AST: Aspartate aminotransferase; ALT: Alanine aminotransaminase; CI: Confidence interval; TS: Transferrin saturation; GGT: γ-glutamyl transferase; BMI: 
Body mass index; p.148M: PNPLA3 rs738409 148Met protein variant.
2817 June 14, 2012|Volume 18|Issue 22|WJG|www.wjgnet.com
1.02-3.55), ferritin > 1000 ng/mL at diagnosis (OR 19.3, 
95% CI: 5.3-125), and with the G allele in patients with 
BMI < 25 (OR 3.26, 95% CI: 1.3-10.3).
DISCUSSION
In this study, we evaluated the effect of  the PNPLA3 
rs738409, encoding for the p.I148M variant, on steatosis 
and liver damage in patients affected by C282Y+/+ HH 
without other causes of  liver damage. Our results con-
firm the association of  the PNPLA3 148M allele with the 
presence of  steatosis and liver enzymes, independently 
of  iron overload, which represents the major cause of  
progressive liver damage in HH patients. Furthermore, 
PNPLA3 rs738409 was also associated with fibrosis 
stage, and with the presence of  cirrhosis, albeit only in 
the presence of  normal BMI. 
Although data on steatosis were not available in the 
whole series of  patients evaluated, the association of  
PNPLA3 with steatosis in HH was expected based on 
data obtained in the general population, in patients with 
non-alcoholic fatty liver disease (NAFLD), and in other 
liver diseases. In addition, the magnitude of  the observed 
association was in line with previous reports[18,19,32]. Due 
to the retrospective design of  the study, insulin resistance 
evaluation was not available for all patients, however, pre-
vious studies have excluded a major effect of  PNPLA3 
genotype on insulin resistance, and the 148M variant was 
not associated with diabetes in this study. 
As steatosis has been reported to influence fibrosis 
progression in C282Y +/+ patients, independently of  
alcohol intake and iron loading[11], the main aim of  the 
present study was to evaluate whether PNPLA3 genotype 
influences liver damage progression in HH. We found 
that the PNPLA3 148M allele was a strong predictor 
of  transaminase levels, and in particular of  AST levels, 
which are generally more strongly linked with chronic 
liver damage (fibrosis stage) than ALT[11,33]. PNPLA3 
polymorphism has been reported to represent a major 
determinant of  transaminase levels in the general popula-
tion, in patients with NAFLD, and in obese subjects at 
risk of  steatosis[18,19,34,35]. Our findings indicate, that this 
is also true for patients with C282Y+/+ HH. It is likely 
that this association reflects the predisposing effect of  
the 148M PNPLA3 allele on steatosis. Interestingly, BMI, 
which was the other determinant of  steatosis in our se-
ries of  patients, was also associated with transaminases. 
Furthermore, we demonstrated that PNPLA3 genotype 
was associated with fibrosis stage in patients with HH, 
consistent with the hypothesis that the 148M allele of  
PNPLA3 influences the progression of  liver damage in 
Table 3  Independent predictors of aspartate aminotransferase and alanine aminotransaminase levels in 174 Italian patients with 
homozygous for the C282Y HFE mutation of hereditary hemochromatosis, in the multivariate generalized linear model
AST ALT
Estimate 95% CI P  value Estimate 95% CI P  value
Age (yr) -0.27 ± 0.09   -0.45 - -0.09     0.0034 -0.55 ± 0.14 -0.81 - -0.27    0.0001
TS (%)  0.14 ± 0.07 -0.01 - 0.29   0.063  0.28 ± 0.11 0.05 - 0.50  0.016
Ferritin (ng/mL)    0.01 ± 0.001   0.008 - 0.012 < 0.0001    0.01 ± 0.001 0.009 - 0.014 < 0.0001
GGT (IU/mL)  0.10 ± 0.03   0.03 - 0.16   0.003  0.20 ± 0.05 0.10 - 0.29 < 0.0001
BMI (kg/m2)  0.86 ± 0.42   0.03 - 1.69   0.042  3.36 ± 0.63 2.12 - 4.60 < 0.0001
PNPLA3 genotype (per p.148M allele)  5.46 ± 1.68   2.15 - 8.67     0.0014  6.05 ± 2.51   1.09 - 11.00   0.017
Table 4  Independent predictors of fibrosis stage in 106 
Italian patients with homozygous for the C282Y HFE 
mutation of hereditary hemochromatosis, at ordinal logistic 
regression analysis
Estimate P  value
Age (yr)    -0.03 ± 0.02   0.077
Gender (female)    -0.57 ± 0.26   0.029
BMI (kg/m2)    -0.08 ± 0.08   0.311
Diabetes     0.57 ± 0.34 0.09
ALT      -0.02 ± 0.008   0.013
GGT (IU/mL)     0.02 ± 0.01   0.035
Ferritin (ng/mL) 0.0001 ± 0.00   0.421
PNPLA3 genotype (per p.148M allele)     0.56 ± 0.27   0.041
BMI: Body mass index; ALT: Alanine aminotransaminase; GGT: γ-glutamyl 
transferase; p.148M: PNPLA3 rs738409 148Met protein variant. 
CC
CG + GG
30
25
20
15
10
5
0
Ci
rr
ho
si
s
BMI < 25                         BMI > 25
   n  = 98                            n  = 76
Figure 3  Effect of the rs738409 G allele, encoding for the 148M PNPLA3 
variant, on liver cirrhosis in 174 patients with HH subdivided according to 
the presence of overweight. NS: Not significant; BMI: Body mass index.
P  = 0.05
P  = NS
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HH, even if  this has to be confirmed in a larger series of  
patients. 
The association of  the 148M variant with the risk of  
cirrhosis, a turning point in the natural history of  patients 
with HH due to the frequent progression to hepatocel-
lular carcinoma[36,37], is also in line with this hypothesis. In-
terestingly, data obtained by our and other groups indicate 
that the 148M variant is significantly associated with cir-
rhosis and hepatocellular carcinoma in patients with HCV-
related chronic hepatitis, thus suggesting that this can be 
true also for liver diseases of  different etiology[32,38].
Based on the previously reported interaction between 
the effect of  the PNPLA3 I148M mutation and body 
mass[35], the other major determinant of  steatosis in our 
series of  patients, we analyzed the effect of  PNPLA3 
rs738409 on cirrhosis risk in patients stratified according 
to the presence of  overweight. We found an association 
between PNPLA3 genotype and cirrhosis, but this was 
restricted to subjects with normal BMI. There are several 
possible explanations for this finding. The first is that the 
result is due to chance. Because of  the relatively limited 
number of  subjects included, the study power to detect 
an association with cirrhosis was relatively low, i.e., > 
85% to detect a two-fold higher risk of  cirrhosis in carri-
ers of  the 148M allele, but only 33% to detect a 33% in-
creased risk. Secondly, this was a retrospective study with 
data evaluation at the time of  diagnosis, therefore we 
could not exclude the fact that some patients “normal-
ized” their body mass after the development of  cirrhosis 
due to the malnutrition typical of  this condition. Howev-
er, increased BMI was independently associated with ste-
atosis and tended to be associated also with cirrhosis risk, 
and the shift in body weight should have equally affected 
patients with and without the 148M allele. Lastly, we can-
not exclude that the PNPLA3 148M variant, by favoring 
steatosis development in subjects with normal BMI, may 
play a permissive role in the progression of  liver damage 
in lean patients with C282Y+/+ HH, whereas in over-
weight subjects steatosis is mainly related to metabolic 
factors, reducing the role played by PNPLA3. Additional 
studies are required to clarify this issue, and to evaluate 
whether the 148M variant may predispose to hepatocel-
lular carcinoma development also in HH and in patients 
carrying HFE mutations[39-41].
In conclusion, we showed that in Italian patients with 
C282Y+/+ HH the PNPLA3 I148M polymorphism 
is associated with the risk of  steatosis, increased liver 
enzymes, higher stage of  fibrosis, and possibly with an 
increased risk of  cirrhosis at diagnosis, particularly in 
subjects with normal body mass. Future studies should 
evaluate whether PNPLA3 I148M genotype might be 
clinically useful for selecting HH patients for biopsy, or 
to determine screening intervals for hepatocellular carci-
noma in cirrhotics.
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